TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12512985
Drug: 3% hydrogen
Normalized name: HYDROGEN PEROXIDE 30 mg in 1 mL TOPICAL LIQUID [3% Hydrogen Peroxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% hydrogen peroxide bleaching gel (Rapid White)
Study: 10661672
Drug: Reinforcement-based intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement-based intensive outpatient treatment (RBT), n = 28
Study: 10661672
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to community treatment resources, n = 24
Study: 8839908
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2, Vinblastine 6 mg/m2, Ifosfamide 3 mg/m2 i.v. on day 1 every 3 weeks (VIP)
Study: 22003960
Drug: Lutein and
Normalized name: ICaps Lutein and Omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein and zeaxanthin supplementation (0.14 + 0.006 mg daily)
Study: 9422174
Drug: Thiopentone therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone therapy (Group A)
Study: 9422174
Drug: No thiopentone
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thiopentone therapy (Group B)
Study: 2476613
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (NTG)
Study: 26152298
Drug: New system
Approvals — FDA: no, EMA: no, PMDA: no
Description: New system of care (structured assessment and treatment algorithms)
Study: 21088114
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol 100/50 μg bid (FP200/S100)
Study: 21088114
Drug: Ciclesonide 160
Normalized name: CICLESONIDE 160MCG 60D ORAL INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide 160 μg once daily (CIC160)
Study: 21191076
Drug: MCC/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCC/Hib vaccine coadministered with PCV7 and MMR vaccine
Study: 21191076
Drug: MCC/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCC/Hib vaccine alone followed by PCV7 with MMR vaccine
Study: 16201128
Drug: 1-week course
Normalized name: ESTRADIOL BENZOATE 1 kg in 1 kg POWDER [Estradiol Benzoate Coarse Grade]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week course of famotidine 40mg b.i.d., amoxicillin 1g b.i.d. and tinidazole 500 mg b.i.d. (FAT1 group; n = 60)
Study: 16201128
Drug: 2-week course
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week course of famotidine 40mg b.i.d., amoxicillin 1g b.i.d. and tinidazole 500 mg b.i.d. (FAT2 group; n = 60)
Study: 16201128
Drug: 1-week course
Normalized name: ESTRADIOL BENZOATE 1 kg in 1 kg POWDER [Estradiol Benzoate Coarse Grade]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-week course of famotidine 40mg b.i.d., amoxicillin 1g b.i.d. and tinidazole 500 mg b.i.d. (FAT1 group; n = 54)
Study: 16201128
Drug: 2-week course
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week course of famotidine 40mg b.i.d., amoxicillin 1g b.i.d. and tinidazole 500 mg b.i.d. (FAT2 group; n = 53)
Study: 11966503
Drug: Clonidine, 0.3
Normalized name: Clonidine, 0.3 mg/24 hr transdermal film, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine, 0.3 mg
Study: 7676701
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intraperitoneal anticancer drugs)
Study: 7423159
Drug: Heparin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (2 x 5000 units subcutaneously/day, first dose 1‐‐2 hours before surgery)
Study: 7423159
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and control combined (independently of heparin administration)
Study: 20397112
Drug: Carbohydrate beverage
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate beverage (6% or 60 grams l(‐1))
Study: 15984599
Drug: Fexofenadine 180
Normalized name: fexofenadine 180 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine 180 mg once daily
Study: 8746201
Drug: Losartan 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 25, 50, 100 mg
Study: 1675370
Drug: DDAVP administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP administered via suction de-epithelialised skin for 4 days
Study: 20337988
Drug: Montelukast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (10 mg orally once daily)
Study: 16613812
Drug: L‐T4 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐T4 monotherapy (Group 1, n=42)
Study: 16613812
Drug: L‐T4 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐T4 monotherapy subgroup with low‐normal TSH
Study: 16613812
Drug: L‐T4+L‐T3 combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐T4+L‐T3 combination therapy (Group 2, n=16)
Study: 12054094
Drug: Antiepileptics
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptics
Study: 29565947
Drug: Conventional analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesics
Study: 10099064
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg benazepril (acute dose)
Study: 10099064
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg benazepril (daily for 1 month)
Study: 2635094
Drug: One daily
Normalized name: One Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily injection of human ultralente
Study: 2635094
Drug: Two daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two daily injections of human ultralente
Study: 2635094
Drug: One daily
Normalized name: One Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: One daily injection of bovine ultralente
Study: 2635094
Drug: Two daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two daily injections of bovine ultralente
Study: 1057909
Drug: Spironolactone 400
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 400 mg/day (S400)
Study: 1057909
Drug: Spironolactone 200
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 200 mg/day (S200)
Study: 31126618
Drug: Ultrasonographically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonographically guided intravenous line placement
Study: 31126618
Drug: Traditional intravenous
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional intravenous line placement
Study: 19210281
Drug: Pharmaceutical Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical Care (PC)
Study: 10355002
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation (INR: 2.0‐3.0)
Study: 10355002
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetylsalicylic acid (30-325 mg/day) plus dipyridamole (400 mg daily)
Study: 10355002
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid only (30-325 mg/day)
Study: 7962781
Drug: Potassium soap
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium soap 7.5% for 20 minutes daily for 8 days
Study: 2663160
Drug: Cefonicid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (1 gm, intravenously or intramuscularly, daily for 3 to 11 days, mean 7 days)
Study: 2663160
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 gm, intravenously or intramuscularly, daily for 3 to 11 days, mean 7 days)
Study: 28865586
Drug: VAC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAC treatment by means of Y-connector
Study: 21586508
Drug: budesonide/formoterol 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide/formoterol 160/4.5 µg, 1 × 2 treatment
Study: 16433868
Drug: Placebo (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (i.v. infusion over 100 min)
Study: 11996479
Drug: Ifosfamide/carboplatin/etoposide (ICE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide/carboplatin/etoposide (ICE) chemotherapy consisting of ifosfamide 1800 mg/m2/day (on day 0-4), carboplatin 400 mg/m2/day (on day 0-1), and etoposide 100 mg/m2/day (on day 0-4)
Study: 11996479
Drug: Ifosfamide/carboplatin/etoposide (ICE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide/carboplatin/etoposide (ICE) chemotherapy
Study: 11996479
Drug: Ifosfamide/carboplatin/etoposide (ICE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide/carboplatin/etoposide (ICE) chemotherapy followed by post-ICE therapy
Study: 6145178
Drug: loprazolam 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: loprazolam 1 mg
Study: 22988932
Drug: SKP-1052 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKP-1052 (2.5 mg)
Study: 22988932
Drug: SKP-1052 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKP-1052 (5 mg)
Study: 19260039
Drug: Cognizin citicoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognizin citicoline 2,000 mg/day
Study: 19260039
Drug: Cognizin citicoline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognizin citicoline 500 mg/day
Study: 17414932
Drug: ATV/r at
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/r at a dose of 300/100 mg once daily (Period I)
Study: 17414932
Drug: ATV at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV at a dose of 300 mg once daily plus LPV/r at a dose of 400/100 mg twice daily (Period II)
Study: 11897259
Drug: Functional energy
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional energy drink (FED) - 250 ml containing sucrose, glucose, 80 mg caffeine, taurine, glucuronolactone, and vitamins
Study: 11897259
Drug: Control drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drink - 250 ml with the same volume and taste but without caffeine, taurine, and glucuronolactone
Study: 17192503
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg d-methylphenidate (d-MPH)
Study: 17192503
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg d-methylphenidate (d-MPH)
Study: 17192503
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg d-methylphenidate (d-MPH)
Study: 17192503
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg d-methylphenidate (d-MPH)
Study: 17192503
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg d-methylphenidate (d-MPH)
Study: 15222108
Drug: Weekly taxol
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly taxol (TXL) therapy at 60 mg/m2 once a week for 3 weeks with or without a rest week.
Study: 12392584
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oseltamivir alone (Treatment A)
Study: 12392584
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oseltamivir with 20 ml Maalox suspension (Treatment B)
Study: 12392584
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg oseltamivir with four Titralac tablets (Treatment C)
Study: 11122796
Drug: Concurrent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin chemotherapy and radiation therapy
Study: 21192268
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone
Study: 18198398
Drug: Iron fortified
Normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron fortified ready-to-eat cereal (30 g providing 7.1 mg iron/day) plus pumpkin seed kernels (30 g providing 4.0 mg iron/day) for four weeks
Study: 7848951
Drug: Intravenous tenoxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tenoxicam (20 mg, 2 mL)
Study: 7848951
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (2 mL)
Study: 29442239
Drug: MA 320
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 320 mg/day plus placebo
Study: 28295847
Drug: Case management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Case management intervention (monthly home visits by nurses and physiotherapists for 1 year)
Study: 8808722
Drug: Chemotherapy (CP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CP protocol)
Study: 8808722
Drug: Post-surgery treatment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-surgery treatment (1 and 3 months) during chemotherapy
Study: 8251920
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) treatment
Study: 19432985
Drug: LPS treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS treatment
Study: 29753474
Drug: 25(OH)D3 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25(OH)D3 treatment
Study: 26836244
Drug: Oral hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hormone therapy (17β-estradiol combined with norethisterone acetate 2 mg + 1 mg/d) for 24 weeks
Study: 21486162
Drug: Soy food
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy food (SF) - 2 to 3 servings per day providing ∼19 g protein and ∼36 mg isoflavones for 10 weeks
Study: 18021495
Drug: 303 Algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 303 Algorithm (insulin detemir)
Study: 15037821
Drug: rosuvastatin 1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 1, 2.5, 5, 10, 20, or 40 mg once daily for 6 weeks
Study: 9169246
Drug: Trazodone (50-250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (50-250 mg/day)
Study: 9169246
Drug: Haloperidol (1-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1-5 mg/day)
Study: 8230008
Drug: Aspirin (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (average 4.5 g daily)
Study: 8230008
Drug: Other NSAIDs
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other NSAIDs (stable doses)
Study: 22577908
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of potassium chloride
Study: 22577908
Drug: Intermittent infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent infusions of potassium chloride
Study: 27586548
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) 3000 mg/day with weight loss diet and 400 IU vitamin E
Study: 24698514
Drug: Calcineurin inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitor toxicity (CNIT)
Study: 22327091
Drug: Whole-body vibration
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body vibration therapy (12 weeks, 12.5 Hz frequency and 3 mm amplitude)
Study: 18830038
Drug: Once-weekly treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly treatment with 17.5 mg risedronate
Study: 18830038
Drug: Once-daily treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily treatment with 2.5 mg risedronate
Study: 1780077
Drug: Dipyridamole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (200 mg b.i.d.) combined with low-dose aspirin (25 mg b.i.d.)
Study: 6358451
Drug: Conventional periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional periodontal treatment with adjunctive metronidazole therapy
Study: 25345429
Drug: PDT-1 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT-1 (600 mg thioctic acid)
Study: 22851967
Drug: Medial branch
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medial branch blocks with local anesthetic and steroids
Study: 17257477
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (75-325 mg/day)
Study: 12480784
Drug: Hyperintense lesions
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperintense lesions (HL) in subcortical gray matter (thalamus and caudate) and associated white matter tracts (internal/external capsule)
Study: 8129609
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride (100 mg) administered twice a day intravenously for 4 days, followed by oral ranitidine hydrochloride (150 mg) administered twice a day for 5 days (n = 11)
Study: 8129609
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant treatment (n = 13)
Study: 4609532
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of marihuana sample B
Study: 4609532
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of marihuana sample C
Study: 4609532
Drug: Delta(9)-THC administered
Normalized name: .DELTA.1-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delta(9)-THC administered to human subjects and laboratory animals
Study: 30540353
Drug: Successful discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful discontinuation of antipsychotic medication regimens
Study: 16427211
Drug: Salvage hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage hormone therapy (HT) initiated after initial treatment
Study: 16427211
Drug: Salvage hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage hormone therapy (HT) for patients with DM absent
Study: 15562184
Drug: Modified low
Normalized name: Minimally modified low density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified low fat diet inclusive of 30 g of walnuts per day
Study: 9402166
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with hematopoietic progenitor cell support (doxorubicin 75 mg/m2, cyclophosphamide 6000 mg/m2, etoposide 800 mg/m2, carboplatin 900 mg/m2, G-CSF 5 microg/kg/d)
Study: 8517510
Drug: High-dose adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adrenaline (10 mg every five minutes)
Study: 8517510
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of adrenaline (1 mg every five minutes)
Study: 3318052
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thiethylperazine and antihistaminic (diphenhydramine)
Study: 3318052
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thiethylperazine and tricyclic antidepressant (amitriptyline)
Study: 24719063
Drug: Topical liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical liposomal Rose Bengal (LRB) gel followed by intense pulsed light (IPL) treatment
Study: 24719063
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel followed by intense pulsed light (IPL) treatment
Study: 22388466
Drug: Ziprasidone (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (35 mg/d)
Study: 12519461
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg haloxazolam (HAX)
Study: 12519461
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg flunitrazepam (FNZ)
Study: 12519461
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg triazolam (TRI)
Study: 1847796
Drug: Intravenous cefoxitin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefoxitin, 1 g every 6 hours for 5 days
Study: 18386570
Drug: Quxie Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quxie Capsule (QXC)
Study: 2104084
Drug: Octreotide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (50 micrograms, single subcutaneous injection)
Study: 31097088
Drug: Oral metronomic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metronomic vinorelbine (OMV) 50 mg three-times weekly
Study: 30114980
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and commitment therapy
Study: 19726290
Drug: Remifentanil preconditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil preconditioning (5 microg/kg in 50 ml normal saline)
Study: 15771036
Drug: Usual postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual postoperative treatment with a pain control program
Study: 9477007
Drug: Risperidone 16
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone 16 mg/day
Study: 7537286
Drug: Haloperidol 20
Normalized name: haloperidol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 20 mg/day
Study: 2737236
Drug: Diclofenac Na
Normalized name: DICLOFENAC NA 1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac Na 100 mg daily for 14 days
Study: 1102233
Drug: Benzquinamide, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzquinamide, 100 mg 3 times daily
Study: 1102233
Drug: Prochlorperazine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine, 10 mg 3 times daily
Study: 28723831
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 7.5 mg